-
Product Insights
Amsterdam Municipality/ NSI – South Axis Wooden Office Building – North Holland
Equip yourself with the essential tools needed to make informed and profitable decisions with our Amsterdam Municipality/ NSI - South Axis Wooden Office Building - North Holland report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – NSI-566
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry NSI-566 Drug Details NSI-566 is under development for the treatment of Amyotrophic lateral sclerosis...
-
Product Insights
Pain Management Devices Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2021
Pain Management Device is used to manage chronic and acute pain in patients suffering from various conditions, such as cancer, neurological disorders, and musculoskeletal disorders. It provides comprehensive information about the Pain Management Devices pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
-
Sector Analysis
Stem Cells in Neurology
Stem cells in neurology is an evolving field. The current pipeline of products feature different types of stem cells and these therapies have the potential to target a range of neurological diseases. However, there are challenges associated with the development of these therapies, including the need to demonstrate strong safety and efficacy data. Biotechnology companies currently dominate in this field and are expected to lead the development of different pipeline products. The current pipeline consists of 16 products (Phase 1,2,...